MX2023006591A - Composiciones y metodos para el tratamiento de enfermedades oculares. - Google Patents
Composiciones y metodos para el tratamiento de enfermedades oculares.Info
- Publication number
- MX2023006591A MX2023006591A MX2023006591A MX2023006591A MX2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A MX 2023006591 A MX2023006591 A MX 2023006591A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- treatment
- eye diseases
- age
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121629P | 2020-12-04 | 2020-12-04 | |
| PCT/US2021/061755 WO2022120137A1 (en) | 2020-12-04 | 2021-12-03 | Compositions and methods for treating ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006591A true MX2023006591A (es) | 2023-08-11 |
Family
ID=81853584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006591A MX2023006591A (es) | 2020-12-04 | 2021-12-03 | Composiciones y metodos para el tratamiento de enfermedades oculares. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240059765A1 (https=) |
| EP (1) | EP4255485A4 (https=) |
| JP (1) | JP2023551734A (https=) |
| KR (1) | KR20230117192A (https=) |
| CN (1) | CN116782940A (https=) |
| AU (1) | AU2021391800A1 (https=) |
| CA (1) | CA3200976A1 (https=) |
| CL (1) | CL2023001596A1 (https=) |
| IL (1) | IL303289A (https=) |
| MX (1) | MX2023006591A (https=) |
| WO (1) | WO2022120137A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3019240T3 (da) | 2013-07-09 | 2024-06-03 | Annexon Inc | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf |
| EP3380518B1 (en) | 2015-11-24 | 2026-03-25 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| US12486322B2 (en) | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
| AU2023262202A1 (en) * | 2022-04-29 | 2024-10-24 | Annexon, Inc. | Compositions and methods for treating ocular diseases. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3019240T3 (da) * | 2013-07-09 | 2024-06-03 | Annexon Inc | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf |
| EP3380518B1 (en) * | 2015-11-24 | 2026-03-25 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
-
2021
- 2021-12-03 CN CN202180090142.XA patent/CN116782940A/zh active Pending
- 2021-12-03 IL IL303289A patent/IL303289A/en unknown
- 2021-12-03 EP EP21901508.8A patent/EP4255485A4/en active Pending
- 2021-12-03 WO PCT/US2021/061755 patent/WO2022120137A1/en not_active Ceased
- 2021-12-03 US US18/265,380 patent/US20240059765A1/en active Pending
- 2021-12-03 MX MX2023006591A patent/MX2023006591A/es unknown
- 2021-12-03 JP JP2023533830A patent/JP2023551734A/ja active Pending
- 2021-12-03 AU AU2021391800A patent/AU2021391800A1/en active Pending
- 2021-12-03 KR KR1020237022463A patent/KR20230117192A/ko active Pending
- 2021-12-03 CA CA3200976A patent/CA3200976A1/en active Pending
-
2023
- 2023-06-02 CL CL2023001596A patent/CL2023001596A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4255485A4 (en) | 2025-05-14 |
| CN116782940A (zh) | 2023-09-19 |
| KR20230117192A (ko) | 2023-08-07 |
| JP2023551734A (ja) | 2023-12-12 |
| US20240059765A1 (en) | 2024-02-22 |
| CL2023001596A1 (es) | 2024-01-19 |
| CA3200976A1 (en) | 2022-06-09 |
| WO2022120137A1 (en) | 2022-06-09 |
| EP4255485A1 (en) | 2023-10-11 |
| IL303289A (en) | 2023-07-01 |
| AU2021391800A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001596A1 (es) | Composiciones y métodos para el tratamiento de enfermedades oculares | |
| AR052172A1 (es) | Inhibicion por arni de ctgf pra el tratamiento de trastornos oculares | |
| CO2023005996A2 (es) | Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea | |
| IL286427B2 (en) | Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease | |
| NZ775964A (en) | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | |
| WO2019209955A3 (en) | Use of pilocarpine hydrochloride for the treatment of ocular conditions | |
| ECSP22086300A (es) | Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas | |
| BR112022005678A2 (pt) | Métodos e composições para o tratamento da retinopatia diabética | |
| AR062395A1 (es) | Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares | |
| MX2021008821A (es) | Derivados de bis (diazirina) como foto-reticulante para el tratamiento de trastornos ectasicos de cornea. | |
| Robert et al. | Collagen cross-linking of the Boston keratoprosthesis donor carrier to prevent corneal melting in high-risk patients | |
| JOP20230133A1 (ar) | استخدام منشطات sGC لمعالجة الأمراض العينية | |
| EA201990752A1 (ru) | Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы | |
| MX2024013187A (es) | Anticuerpos biespecíficos y métodos de tratamiento de las enfermedades oculares | |
| ZA202309651B (en) | Compositions and methods for treatment of ocular disease associated with angiogenesis | |
| CO2024012414A2 (es) | Agentes de interferencia de arn de sarm1 | |
| BR112019022912A2 (pt) | Métodos e composições para tratar doenças oculares alérgicas | |
| MX2022011234A (es) | Composiciones y métodos para la salud ocular que comprenden ácidos grasos de cadena muy larga. | |
| MX2021014682A (es) | Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos. | |
| PE20240228A1 (es) | Gotas para los ojos para tratar el adelgazamiento de la esclerotica y metodo de cribado para el agente terapeutico del adelgazamiento de la esclerotica | |
| JPWO2019181967A1 (ja) | 非侵襲的角膜又は強膜強化装置 | |
| BR112022018113A2 (pt) | Composições e métodos para saúde ocular compreendendo areds e complexo de vitamina b | |
| CL2024003281A1 (es) | Anticuerpos específicos contra la proteína 7 relacionada con la angiopoyetina y usos de estos | |
| BR112022003759A2 (pt) | Método e uso de pnpp-19 para prevenção e tratamento de doenças oculares | |
| BRPI0517972A (pt) | ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas |